Biolexis Therapeutics develops oral small‑molecule drugs that target metabolic pathways to treat obesity and type 2 diabetes. Its lead candidates include an allosteric GLP‑1 receptor agonist and an isoform‑selective AMPK activator, which together aim to provide injectable‑like efficacy, improve insulin sensitivity, and preserve lean muscle mass without injections or gastrointestinal side effects.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Obesity, type 2 diabetes, and related metabolic disorders remain prevalent, and existing therapies often require injections, have gastrointestinal side effects, or cause loss of lean muscle mass, limiting patient adherence and long‑term health outcomes.
Solution
Biolexis Therapeutics develops next‑generation oral small‑molecule drugs that target metabolic pathways with novel mechanisms. Its lead candidates include BLX‑7006, an allosteric GLP‑1 receptor agonist designed to deliver injectable‑like efficacy for weight loss and glycemic control in a once‑daily pill, and BLX‑0871, an isoform‑selective AMPK activator that enhances muscle glucose uptake and preserves lean mass. By combining these agents in a dual‑mechanism oral regimen, the company aims to provide effective weight reduction, improved insulin sensitivity, and muscle‑sparing benefits without the need for injections or the gastrointestinal adverse events typical of current GLP‑1 therapies. Early Phase I trials are evaluating safety, tolerability, and pharmacokinetics, with plans for combination studies in 2026.
Target Audience
Primary customers are pharmaceutical partners and healthcare providers seeking oral therapies for obesity, type 2 diabetes, and metabolic health, as well as patients who require effective, needle‑free treatment options with minimal side effects.
Features
- Oral small‑molecule GLP‑1 receptor agonist (BLX‑7006) that binds an allosteric site, enabling cooperative activation with endogenous GLP‑1 and reducing desensitization.
- Isoform‑selective AMPK activator (BLX‑0871) targeting the γ3‑rich skeletal‑muscle complex, enhancing fatty‑acid oxidation, glucose uptake, and mitochondrial function while avoiding cardiac activation.
- Dual‑mechanism formulation that couples GLP‑1 agonism with muscle‑sparing AMPK activation to achieve weight loss without lean‑mass loss.
- Phase I clinical programs assessing safety, tolerability, and pharmacokinetics in healthy volunteers for both single agents and the planned combination.
- Proprietary MolecuLern platform supporting discovery of oral small‑molecule therapeutics with optimized chemotypes and target selectivity.
- Patent‑protected chemical scaffolds and IND‑ready candidates covering both GLP‑1 and AMPK pathways.